What Felo Treats: Main Uses and Benefits

Felo is primarily used for the long-term management of essential hypertension, addressing symptoms related to systemic imbalance and heightened physiological activity in adults. The medication may assist with easing symptoms that are associated with chronic stable angina pectoris. Its use is relevant in conditions marked by increased physiological stress, and helps in the management of high blood pressure.

The therapeutic approach is relevant in contexts involving heightened systemic burden. The therapeutic scope includes conditions presenting with sustained elevation of blood pressure and symptoms related to physical discomfort. By helping to consistently lower blood pressure levels, the medication provides supportive relief, which may assist with maintaining functional stability and supports the patient's long-term vascular health.

The medication is applied in addressing symptomatic areas linked to organ-specific functional stress, which may assist with **maintaining functional stability.

---

Quick Fact: Symptomatic Support for Systemic Imbalance
Felo is applied across domains where additional symptomatic support is needed, primarily for conditions involving sustained systemic pressure and episodic physical discomfort.

---

Who Can and Cannot Use Felo?

Eligibility for Felo (Felodipine extended-release) is strictly defined by regulatory authorities and centers on age, underlying health conditions, and specific physiological states.

Approved and Excluded Populations

Category	Regulatory Status
Approved Population	Adults are the only group for whom use is officially established for treating hypertension and chronic stable angina.
Pediatric Use	Safety and efficacy have not been established in children and adolescents, meaning use is not authorized for this population.
Pregnancy Status	Contraindicated. The medicine must not be given during pregnancy.
Lactation Status	Not recommended due to insufficient data on potential infant effects, as the drug may be present in breast milk.

---

Absolute Contraindications

The medicine must not be used by patients with specific health conditions, as defined in regulatory labeling. These absolute prohibitions include:

• Known hypersensitivity to felodipine or any component of the tablet.
• Acute myocardial infarction or unstable angina pectoris.
• Decompensated heart failure.
• Significant cardiac outflow obstruction, such as specific valvular or dynamic obstructions.

Conditional Use

Patients with impaired hepatic function require special caution because their body may process the drug slower, potentially leading to higher concentrations. Older adults may also require closer monitoring and consideration for a lower starting dose.

Interactions with other medicines and products

Felo (Felodipine) is primarily metabolized by the CYP3A4 enzyme system, which dictates its most significant interaction patterns documented in regulatory labeling.

---

Pharmacokinetic Interactions

Co-administration with substances that modify CYP3A4 activity can significantly alter the exposure (plasma concentration) of Felodipine. Combinations with potent enzyme modulators are associated with the greatest risk.

Interaction Type	Examples	Official Outcome
Potent CYP3A4 Inhibitors	Itraconazole, Ketoconazole	Substantial increase in Felodipine exposure (up to 8-fold increase in AUC); combination is officially designated to be avoided.
Potent CYP3A4 Inducers	Phenytoin, Rifampicin, St John's wort	Significant decrease in Felodipine plasma levels; combination is designated to be avoided.

---

Other Documented Interactions

Substance Type	Specific Examples	Official Restriction
Food Product	Grapefruit Juice	Documented to increase Felodipine bioavailability by more than two-fold; consumption should be avoided.
Co-administered Drug	Tacrolimus	Felodipine may increase the blood concentration of Tacrolimus, requiring monitoring and potential dose adjustment of the co-administered drug.

---

The official interaction profile notes that Felodipine clearance is reduced in patients with hepatic disease, leading to higher baseline plasma concentrations, which may amplify the effects of co-administered metabolic inhibitors.

How Felo Works

The active ingredient, Felodipine, operates through a sequence of biological events that alters the vascular muscle tone. Its action involves a mechanism focused on a specific ion channel in the peripheral circulation.

Molecular Action on L-Type Calcium Channels

Felodipine engages mechanisms that alter cellular processes by selectively targeting and blocking the L-type Voltage-Dependent Calcium Channels ( L-VDCCs) found in arteriolar smooth muscle cell membranes. This mechanism initiates or suppresses signaling sequences by preventing the influx of extracellular calcium ions ( Ca^2+) that mediate muscle contraction.

Modulation of Vascular Tone and Contraction

The inhibition of Ca^2+ influx modifies early molecular steps, causing a reduction in the concentration of Ca^2+ inside the muscle cells, which halts the activation of the contraction-initiating enzyme ( MLCK). This suppression of the calcium-dependent pathway leads directly to arteriolar smooth muscle relaxation (vasodilation).

Physiological Effect on Systemic Resistance

The resulting relaxation of the arteries leads to a physiological adjustment: a widespread decrease in the Peripheral Vascular Resistance (PVR) throughout the systemic circulation. This systemic change is characterized by a reduction in Peripheral Vascular Resistance (PVR).

How to Use Felo: Official Administration Guidelines

Felo, which contains the active ingredient felodipine, is administered orally as a single extended-release tablet. The formulation is designed to release the medicine over a 24-hour period, necessitating that the tablet must be swallowed whole and must not be crushed, broken, or chewed under any circumstances.

Administration occurs once daily, preferably taken in the morning. The tablet should be taken with water, either without food or alongside a light meal low in fat and carbohydrates. It is an official procedural condition that grapefruit juice must be entirely avoided due to its potential to interfere with the intended absorption of the medication.

Dosing Regimens (Adults)	Regulatory Instruction
Initial Dose	5 mg once daily
Maximum Dose	10 mg once daily

The course of administration is intended for long-term use. Dose adjustments, if deemed appropriate, must be conducted gradually, with an interval of no less than two weeks between changes. This allows sufficient time for the new dosage to achieve a stable effect.

Special Population Rules	Required Initial Dose
Older Adults	2.5 mg once daily
Hepatic Impairment	2.5 mg once daily

If a dose of Felo is missed, the official procedure is to skip the missed dose and simply take the next scheduled dose at the usual time; the dose should not be doubled.

Research Evidence / Overview of Studies for Felo

Evidence for Use in Essential Hypertension

This section will summarize the types of research available for research exploring Felo's evaluation in high blood pressure, including studies that measured blood pressure changes, assessed the attainment of target levels, and those that observed long-term cardiovascular outcomes.

The research context for Felo's evaluation in essential hypertension involves Randomized Controlled Trials (RCTs), comparative efficacy trials, and systematic reviews. Researchers have primarily studied adult populations characterized by mild-to-moderate hypertension. Key outcomes that were monitored in these studies include measuring changes in systolic and diastolic blood pressure (BP) readings and evaluating the proportion of participants who reached predefined target BP levels.

Studies have also explored the effect of Felo on structural changes associated with long-term high blood pressure, such as changes in the size of the heart muscle (Left Ventricular Hypertrophy, or LVH). Patterns in blood pressure evolution during the study period are described, and this research contributes to the broader evidence landscape for this pharmacological class.

Evidence for Use in Chronic Stable Angina Pectoris

This section will detail the clinical trial designs, such as short-term randomized studies, that focused on research exploring Felo's evaluation for symptomatic support in chronic stable angina pectoris, including the measurement of outcomes like angina frequency and exercise capacity.

For chronic stable angina pectoris, research has primarily included RCTs designed to evaluate outcomes related to physical discomfort and episodic changes. Studies explored changes in the measured frequency and intensity of angina attacks and monitored the reported use of rescue medications. Furthermore, research examined functional measures, such as measured changes in exercise tolerance capacity and activity level, often over short-to-intermediate follow-up durations.

Long-Term Research and Sustained Observation Periods

This part of the outline will describe the extended follow-up periods found in major clinical programs for Felo and its drug class, specifically addressing what research has examined regarding the maintenance of observed effects and any data available on cardiovascular morbidity and mortality events over several years.

Some research includes extended observation periods, often several years, which contributes to the understanding of long-term outcomes and the maintenance of the initial blood pressure changes observed. These extended studies were often observational or comparative, going beyond the short-term focus of typical efficacy trials. They examined event rates for major cardiovascular outcomes and mortality, which is relevant in evidence describing how outcomes are measured in long-term observational settings.

Common questions about Felo (FAQ)

---

Q: What should I do if I forget to take my daily dose?

The official administration instruction advises that if a dose of Felo is missed, the patient should skip the missed dose completely. The next dose should then be taken at the usual scheduled time. It is specified that the dose should not be doubled to compensate for the missed one.

---

Q: How long does it typically take for Felo to start working after I take it?

Felo is formulated as an extended-release tablet designed for once-daily dosing and to provide a sustained effect over 24 hours. Regulatory information, specifically the clinical pharmacology data, documents the time it takes for the maximum concentration of the drug to appear in the bloodstream (T max). This sustained-release design is intended to maintain consistent therapeutic levels that support ongoing blood pressure control.

---

Q: What are the common side effects of Felo?

Official safety data lists the most frequently reported adverse reaction as peripheral edema, which is swelling in the hands, ankles, or feet. Other common side effects documented in official labeling include headache and flushing (reddening of the skin).

---

Q: Can Felo be used to treat other conditions besides high blood pressure?

Official labeling states that Felo is indicated only for the management of essential hypertension and the symptomatic treatment of chronic stable angina pectoris. Its use is limited to the conditions specified in the official regulatory documents.

---

Q: How long after starting Felo can I expect my blood pressure to be fully controlled?

Studies and official information indicate that blood pressure control with Felo is achieved gradually. Dose adjustments, if needed, are conducted with an interval of no less than two weeks between changes. This two-week interval is required to allow the new dosage sufficient time to achieve a stable effect and for the full clinical results to be assessed.

---

Q: What are the signs or symptoms of an overdose of Felo?

Overdose with Felo may result in effects related to its primary action as a potent vasodilator. The main signs documented in the prescribing information include marked low blood pressure (hypotension) and a very slow heart rate (bradycardia). Specific procedures for the clinical management of an overdose are detailed in the official safety documents.

---

Q: Can I breastfeed while taking Felo?

Official regulatory guidance advises against the use of Felo during breastfeeding. This recommendation is based on insufficient data regarding the drug's potential presence in breast milk and the unknown effects on the nursing infant.

The storage and disposal of Felo (Felodipine extended-release tablets) must follow specific regulatory requirements to ensure product stability.

Storage Requirements

Felo must be stored at Controlled Room Temperature, between 20 C and 25 C (68 F and 77 F) [1.1, 2.5]. Temperatures should not exceed 30 C [1.1]. The medication must be kept in its container, which should be tightly closed, and stored away from excess heat and moisture [2.1]. The tablets must also be kept out of the reach of children [2.1].

Disposal Instructions

Unused or expired Felo must be disposed of according to official local and national guidelines [2.1]. Do not flush the tablets down a toilet or pour them into a drain [2.5]. The recommended method is to use a drug take-back program or mail-back option [2.6]. If neither is available, tablets should be mixed with an undesirable substance (e.g., used coffee grounds) and placed in a sealed container before throwing in the household trash [2.6].